1Anton A, Hornedo J, Lluch A, et al. A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer[J]. Clin Breast Cancer,2003,4(4):286-291
2Morales S, Lorenzo A, Ramos M, et al. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study[J]. Cancer Chemother Pharmacol,2004,53(1):75-81
3Smith RE, Anderson SJ, Brown A, et al. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58[J]. Clin Breast Cancer,2002,3(5):333-340
4Bonneterre JM, Dieras V, Tubiana-Hulin M, et al. Epirubicin/docetaxel versus 5FU/epirubicin/cyclophosphamide combinations as first line chemotherapy in patients with metastatic breast cancer[J]. Breast Cancer Research and Treatment. Special issue: 24th An
5NSABP Investigators. The effect of primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27[J]. Breast Cancer Research and Treatment.Special issue: 24th Annual San Antonio Breast
6Ali SM, Harvey HA, Lipton A.Metastatic breast cancer: overview of treatment[J].Clin Orthop,2003,(415 Suppl):S132-137
